Revolution Medicines, Inc. is 4.8x more valuable than Kymera Therapeutics, Inc. by market capitalization ($30.65 B vs $6.44 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KYMR | RVMD |
|---|---|---|
| Market cap | $6.44 B | $30.65 B |
| US-listed rank | #1211 | #454 |
| Revenue (latest FY) | $39.21M | $0.00 |
| Net income (latest FY) | $311.35M | -$1.13B |
| Net margin | 794.0% | - |
| P/E (trailing FY) | 20.7 | - |
| SEC filings | 575 | 782 |
Revolution Medicines, Inc. is 4.8x more valuable than Kymera Therapeutics, Inc. by market capitalization ($30.65 B vs $6.44 B).
In their latest fiscal years, Kymera Therapeutics, Inc. reported $39.21M in revenue while Revolution Medicines, Inc. reported $0.00.
Full pages: Kymera Therapeutics, Inc. and Revolution Medicines, Inc., or browse the full rankings.